Top Markets
#1 Helium Helium +77.57%
#2 Seeker Seeker +52.14%
#3 Pons Pons +33.69%
#4 UnifAI Network UnifAI Network +29.95%
#5 TENDIES TENDIES +26.41%
#6 Tensor Tensor +23.80%
#7 Zylo Ecosystem Zylo Ecosystem +21.90%
#8 pipedog pipedog +17.97%
#9 Bounce Bounce +16.14%
#10 Songbird Songbird +15.11%
Coin of the day
Helium Helium
सेटिंग्स
भाषा
हिन्दी
मुद्रा
USD
थीम
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
शेयरों में रैंक #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
शेयर मूल्य
$9.50
अंतिम समन्वयन: 2025-01-08
मार्केट कैप
$819.52M
बदलाव (1 दिन)
0.00%
बदलाव (1 वर्ष)
0.00%
देश
US
व्यापार Poseida Therapeutics, Inc. (PSTX)

श्रेणी

Healthcare
Poseida Therapeutics, Inc. (PSTX) के लिए P/B अनुपात
August 2026 को P/B अनुपात TTM: 8.26
Poseida Therapeutics, Inc. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी का वर्तमान P/B अनुपात (TTM) 8.26 है। 2022 के अंत में, कंपनी का P/B अनुपात 2.03 था।
Poseida Therapeutics, Inc. के लिए 2016 से 2026 तक P/B अनुपात का इतिहास
हर वर्ष के अंत में P/B अनुपात
वर्ष P/B अनुपात परिवर्तन
2026 (TTM) 8.26 182.94%
2023 2.92 43.83%
2022 2.03 -25.05%
2021 2.71 10.84%
2020 2.45 -159.95%
2019 -4.08 -43.25%
2018 -7.19 -60.46%
2017 -18.18 -132.79%
2016 55.46 0.00%
समान कंपनियों या प्रतिस्पर्धियों के लिए P/B अनुपात
कंपनी P/B अनुपात P/B अनुपात में अंतर देश
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -23.24%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -24.46%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -69.67%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -55.11%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH